Term
|
Definition
| Dyslipidemia- inhibits adipose lipase, and reduces TG esterfication. ↓ VLDVL, TG, LDL. ↑ HDL tPA |
|
|
Term
| Fenofibrate (TriCore, Triglide, Trilipix) |
|
Definition
| Dyslipidemia- (Fibrate) PPAR α Agonist, ↓ serum TG,VLDL. ↑ HDL slightly. No effect on LDL |
|
|
Term
|
Definition
| Dyslipidemia- (Fibrate) PPAR α Agonist, ↓ serum TG,VLDL. ↑ HDL slightly. No effect on LDL |
|
|
Term
| Cholestyramine (Questran) |
|
Definition
| Dyslipidemia- (Bile acid Sequestrant) binds to bile acids (precursors to cholesterol) shifts synthesis toward bile acids rather than cholesterol. AE abd cramp, consti, impaction |
|
|
Term
|
Definition
| Dyslipidemia- (Bile acid Sequestrant) binds to bile acids (precursors to cholesterol) shifts synthesis toward bile acids rather than cholesterol. AE abd cramp, consti, impaction |
|
|
Term
|
Definition
| Dyslipidemia- (Bile acid Sequestrant) binds to bile acids (precursors to cholesterol) shifts synthesis toward bile acids rather than cholesterol. Newer, more potent, smaller dosees |
|
|
Term
|
Definition
| Reduce major coronary events, reduce CHD mortality |
|
|
Term
|
Definition
| Dyslipidemia- (Cholesterol Absorption Inhibitor) blocks lipase, ↓ intestinal absorption of cholesterol 17%, TG 6% |
|
|
Term
| HMG-CoA Reductase inhibitors |
|
Definition
| -'statin'. Dyslipidemias- inhibit rate limiting enzyme in cholesterol synthesis. |
|
|
Term
|
Definition
| Dyslipidema- HMG-CoA Reductase inhibitor. ↓ LDL, TG, VLDL and total cholesterol 20-50%, increase HDL |
|
|
Term
|
Definition
| Dyslipidema- HMG-CoA Reductase inhibitor. ↓ LDL, TG, VLDL and total cholesterol 20-50%, increase HDL. 1st statin |
|
|
